[go: up one dir, main page]

WO2005027887A3 - Methods and compositions for improving endothelial function - Google Patents

Methods and compositions for improving endothelial function Download PDF

Info

Publication number
WO2005027887A3
WO2005027887A3 PCT/US2004/030587 US2004030587W WO2005027887A3 WO 2005027887 A3 WO2005027887 A3 WO 2005027887A3 US 2004030587 W US2004030587 W US 2004030587W WO 2005027887 A3 WO2005027887 A3 WO 2005027887A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
endothelial function
improving endothelial
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/030587
Other languages
French (fr)
Other versions
WO2005027887A2 (en
Inventor
Alan M Ezrin
Alan Moore
Gregory N Beatch
Lewis S L Choi
Thomas Munzel
Stephan Baldus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CARDIMONE PHARMA Corp
Original Assignee
CARDIMONE PHARMA Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CARDIMONE PHARMA Corp filed Critical CARDIMONE PHARMA Corp
Publication of WO2005027887A2 publication Critical patent/WO2005027887A2/en
Publication of WO2005027887A3 publication Critical patent/WO2005027887A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to methods, compositions, and uses for improving impaired endothelial function associated with vascular disease. More particularly the invention relates to methods, compositions and uses comprising xanthine oxidase inhibitors to treat and/or prevent coronary artery disease or coronary heart disease, and related diseases or conditions.
PCT/US2004/030587 2003-09-17 2004-09-17 Methods and compositions for improving endothelial function Ceased WO2005027887A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50405903P 2003-09-17 2003-09-17
US60/504,059 2003-09-17
US60842304P 2004-09-08 2004-09-08
US60/608,423 2004-09-08

Publications (2)

Publication Number Publication Date
WO2005027887A2 WO2005027887A2 (en) 2005-03-31
WO2005027887A3 true WO2005027887A3 (en) 2005-06-23

Family

ID=34381096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/030587 Ceased WO2005027887A2 (en) 2003-09-17 2004-09-17 Methods and compositions for improving endothelial function

Country Status (1)

Country Link
WO (1) WO2005027887A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948183B1 (en) * 2005-10-13 2013-12-18 Duke University Compositions for the treatment and prevention of heart disease and methods of using same
GB0909243D0 (en) * 2009-05-29 2009-07-15 Univ Dundee Angina treatment
IT1400310B1 (en) * 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND STATINES AND THEIR USE.
IT1400311B1 (en) * 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa ASSOCIATION OF INHIBITORS OF XANTHIN OXIDASE AND ANTAGONISTS OF THE Angiotensin II RECEPTOR AND THEIR USE.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024038A1 (en) * 1997-11-07 1999-05-20 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
WO2001025192A1 (en) * 1999-10-06 2001-04-12 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
WO2003043573A2 (en) * 2001-11-16 2003-05-30 The Uab Research Foundation Xanthine oxidase inhibition
WO2004060489A2 (en) * 2002-12-20 2004-07-22 Tap Pharmaceutical Products Inc. Treatment of chronic heart failure

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024038A1 (en) * 1997-11-07 1999-05-20 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
US6569862B1 (en) * 1997-11-07 2003-05-27 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
WO2001025192A1 (en) * 1999-10-06 2001-04-12 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
WO2003043573A2 (en) * 2001-11-16 2003-05-30 The Uab Research Foundation Xanthine oxidase inhibition
WO2004060489A2 (en) * 2002-12-20 2004-07-22 Tap Pharmaceutical Products Inc. Treatment of chronic heart failure

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ABU-SOUD H M ET AL: "Nitric oxide modulates the catalytic activity of myeloperoxidase", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 8, 25 February 2000 (2000-02-25), pages 5425 - 5430, XP002268584, ISSN: 0021-9258 *
C.A. FARQUHARSON ET AL: "Allopurinol improves endothelial dysfunction in chronic heart failure", CIRCULATION, vol. 106, no. 2, 9 July 2002 (2002-07-09), pages 221 - 226, XP002320665 *
DOEHNER W ET AL: "Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 105, no. 22, 4 June 2002 (2002-06-04), pages 2619 - 2624, XP002278503, ISSN: 0009-7322 *
MIYAMOTO Y ET AL: "POTENTIATION OF NITRIC OXIDE-MEDIATED VASORELAXATION BY XANTHINE OXIDASE INHIBITORS (43982)", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY & MEDICINE, ACADEMIC PRESS INC. NEW YORK, US, vol. 211, no. 4, 1996, pages 366 - 373, XP002041196, ISSN: 0037-9727 *
S. GUTHIKONDA ET AL: "Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers", CIRCULATION, vol. 107, no. 3, 28 January 2003 (2003-01-28), pages 416 - 421, XP002320664 *
SOBEY C G ET AL: "IMPAIRED ENDOTHELIUM-DEPENDENT RELAXATION OF DOG CORONARY ARTERIES AFTER MYOCARDIAL ISCHAEMIA AND REPERFUSION: PREVENTION BY AMLODIPINE, PROPRANOLOL AND ALLOPURINOL", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 105, no. 3, March 1992 (1992-03-01), pages 557 - 562, XP000953137, ISSN: 0007-1188 *
UPCHURCH G R ET AL: "HEPARIN REACTS WITH AND INACTIVATES NITRIC OXIDE", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, CHURCHILL LIVINGSTONE, NAPERVILE, IL, US, vol. 6, no. 2, April 2001 (2001-04-01), pages 163 - 173, XP008006019, ISSN: 1074-2484 *

Also Published As

Publication number Publication date
WO2005027887A2 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
WO2004103960A3 (en) Compounds and uses thereof
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
BRPI0307673A2 (en) methods of treating vascular disease.
WO2008002576A3 (en) Prolyl hydroxylase inhibitors and methods of use
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
EP2332527A3 (en) Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003248245A1 (en) Remedies for diseases caused by vascular contraction or dilation
WO2005001079A3 (en) Soft tissue repair and regeneration using postpartum-derived cells
WO2005117858A3 (en) Compositions comprising nebivolol
WO2009017863A3 (en) Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
WO2004028516A3 (en) Compositions for the inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2006034235A3 (en) Substituted quinoline and quinazoline inhibitors of quinone reductase 2
WO2005049084A3 (en) Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
WO2004039248A3 (en) Repairing or replacing tissues or organs
WO2003103662A3 (en) Inhibitors of glycoprotein vi
NO20064489L (en) Sulfated oligosaccharide derivatives
WO2005004814A3 (en) Sirt1 and genetic disorders
AU2003222513A1 (en) Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
WO2006057674A3 (en) COMPOSITIONS AND METHODS FOR EX VIVO PRESERVATION OF BLOOD VESSELS FOR VASCULAR GRAFTS USING ANALOGUES OF cAMP AND cGMP
WO2006122046A3 (en) Vascular disease therapies
WO2004091436A3 (en) Methods and compositions for treating ocular disease
WO2006013261A3 (en) Use of gingival fibroblasts for vascular cell therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase